The long term objective of this research is to produce an effective vaccine against respiratory syncytial virus (RSV), human parainfluenza virus-type 1 (hPIV-1) and human parainfluenza virus-type 3 (hPIV-3). Sendai virus (mouse PIV-1) has proven effective as a vaccine for hPIV-1 in non-human primate studies, and developments in reverse genetic engineering now permit additional genes to be inserted as passengers in the Sendal virus genome. The recombinant Sendal viruses (rSV) that incorporate passenger genes for membrane proteins of other respiratory viral pathogens may thus provide protective immunity both to hPIV-1 and to the other viruses. To provide a foundation for the confident formulation of vaccines to be tested in primates and humans, this section proposes an extensive course of experimentation to establish safety and efficacy in a laboratory rodent model, the cotton rat (Sigmodon hispidus), in which human respiratory viruses grow well after intranasal inoculation. Initial Specific Aims in this project involve testing and comparing individual strains of rSV that carry genes for the attachment and fusion proteins of RSV or hPIV-3. Experiments are designed to assess the vigor of the humoral and cellular immune responses generated by rSV inoculations, and to evaluate associated protective immunity and immunopathological reactions. Our last Aim is to test increasingly complex combinations of rSV strains, with the final objective of formulating an optimized rSV cocktail that will function safely and effectively to provide protection from RSV, hPIV-1 and hPIV-3. Studies proposed in this Project (Project 2) will be highly interactive with Projects 1 and 3. Products and concepts from Project 1 will support each of the Specific Aims, which will, in turn, support the non-human primate and clinical studies in Project 3. Ultimately, we propose that the research from this interactive Program Project will yield a safe, effective and affordable respiratory virus vaccine for children.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI054955-05
Application #
7624654
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2008-11-30
Support Year
5
Fiscal Year
2008
Total Cost
$252,662
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Russell, Charles J; Jones, Bart G; Sealy, Robert E et al. (2017) A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Virology 509:60-66
Russell, Charles J; Hurwitz, Julia L (2016) Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines 15:189-200
Zhan, Xiaoyan; Slobod, Karen S; Jones, Bart G et al. (2015) Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats. Int Immunol 27:229-36
Adderson, Elisabeth; Branum, Kristen; Sealy, Robert E et al. (2015) Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin Vaccine Immunol 22:298-303
Rudraraju, Rajeev; Sealy, Robert E; Surman, Sherri L et al. (2013) Non-random lymphocyte distribution among virus-infected cells of the respiratory tract. Viral Immunol 26:378-84
Rudraraju, Rajeev; Jones, Bart G; Sealy, Robert et al. (2013) Respiratory syncytial virus: current progress in vaccine development. Viruses 5:577-94
Jones, B G; Hayden, R T; Hurwitz, J L (2013) Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model. Antiviral Res 100:562-6
Rudraraju, Rajeev; Surman, Sherri L; Jones, Bart G et al. (2012) Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient mice. Clin Vaccine Immunol 19:757-65
Jones, Bart G; Sealy, Robert E; Rudraraju, Rajeev et al. (2012) Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30:959-68
Rudraraju, Rajeev; Surman, Sherri; Jones, Bart et al. (2011) Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology 410:429-436

Showing the most recent 10 out of 19 publications